

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

**VOLUNTARY ANNOUNCEMENT
ROTIGOTINE LUYE TRANSDERMAL PATCH
LAUNCHED IN THE UNITED KINGDOM**

The board of directors (the “**Board**”) of Luye Pharma Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that the Group has launched its rotigotine transdermal patch, Rotigotine Luye, in the United Kingdom (the “**UK**”) for the treatment of the signs and symptoms of early-stage and advanced idiopathic Parkinson’s disease (“**PD**”), as well as moderate-to-severe idiopathic restless legs syndrome (“**RLS**”) in adults. Rotigotine Luye is the first generic transdermal patch launched in the UK that demonstrates bioequivalence to Neupro®.

Rotigotine Luye patches have the same dosage strengths as Neupro® patches. At the equivalent dosage strength, a Rotigotine Luye patch is 8% smaller in size and has a lower drug load compared to a Neupro® patch. Furthermore, unlike Neupro® patches, the adhesive substrate of Rotigotine Luye patches does not contain sodium metabisulfite, a known contact allergen that may cause allergic reactions.

PD is the second most common neurodegenerative disorder worldwide, affecting over 10 million people. This condition leads to impaired mobility as well as mental disorders, sleep disorders, pain and other health issues. Its symptoms would progressively worsen over time and significantly compromises the patients’ well-being and quality of life. RLS is a common neurosensory disorder affecting approximately 3% of the global population. Characterized by an overwhelming and irresistible urge to move the patient’s legs, this condition can significantly disrupt the daily activities of patients in severe cases. Rotigotine, which acts as a dopamine agonist, can improve the motor and non-motor function of PD patients and can provide an effective symptom relief for those with RLS.

Rotigotine Luye is the sixth product launched by the Group that provides central nervous system (“CNS”) treatment in the UK. Aside from the UK market, it has also successfully launched in Germany. The Group plans to expand the product’s availability by launching it in several other countries through collaborations with its partners. Rotigotine Luye is produced by the Group’s manufacturing facility in Germany. This facility has specialized in transdermal drug delivery technology for over 20 years and is currently one of the largest independent manufacturers of transdermal patches in Europe.

The Group maintains a long-term commitment to the field of CNS treatment, developing a range of internationally competitive and innovative drugs and formulations. The Group’s product portfolio includes: Erzofri® (paliperidone palmitate) extended-release injectable suspension and Rykindo® (risperidone) for extended-release injectable suspension, both of which have been approved for marketing in the United States; and Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets) and Jinyouping® (Rotigotine Microspheres for Injection), both of which have been approved for marketing in China. In addition, the Group is conducting clinical studies for several Class 1 innovative drugs, including: LY03020, a dual agonist which targets TAAR1/5-HT_{2C}R; LY03021, a new drug which targets NET/DAT/GABA_AR; and LY03015, a new drug which targets VMAT2/Sigma1.

By Order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 10 April 2025

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Mr. HUANG Liming; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.